Compare PRTH & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTH | LBRX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.8M | 563.2M |
| IPO Year | N/A | 2025 |
| Metric | PRTH | LBRX |
|---|---|---|
| Price | $5.79 | $20.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $49.00 |
| AVG Volume (30 Days) | 363.3K | ★ 518.2K |
| Earning Date | 11-06-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $932,948,000.00 | N/A |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | $10.25 | ★ N/A |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $4.44 | $13.36 |
| 52 Week High | $12.47 | $23.15 |
| Indicator | PRTH | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | N/A |
| Support Level | $5.43 | N/A |
| Resistance Level | $5.66 | N/A |
| Average True Range (ATR) | 0.20 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 73.94 | 0.00 |
Priority Technology Holdings Inc is a provider of merchant acquiring and commercial payment solutions to small and medium business enterprises in the United States. The company has three reportable segments which are SMB Payments, B2B Payments, and Enterprise Payments. SMB Payments segment which generates the majority of revenue provides full-service acquiring and payment-enabled solutions for B2C transactions, leveraging Priority's proprietary software platform, distributed through ISO; the B2B Payments segment provides AP automation solutions to corporations, software partners, & industry FIs: and Enterprise Payments segment provides embedded payment & treasury solutions to enterprise customers to modernize legacy platforms & accelerate software partners' strategies to monetize payments.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.